A case series to report CDK4/6 induced Vitiligo.

Study Methodology: This is an observational study of patients, who are currently on CDK4/6 inhibitors, i.e. Tab Ribociclib or Tab Palbociclib. Patients will be consented for the study, during their routine follow-up visit. Photographic images will be taken for the records. No treatment interventions will be done. Patient’s demographic and medical history will be noted, to study any common correlations among the reported cases if any. The second optional part of the study will be to acquire biopsy from the vitiligo affected area. It will be taken from patients, who will consent for it. Biopsy will be an optional procedure, and denying it will not affect the main study enrollment. A separate ICF will be used for consenting from patients who will be willing for the skin biopsy. Punch biopsy will be done from hypopigmented patches and subjacent healthy skin. Loss of Melanin pigment will be graded as partial or complete as opposed to adjacent normal skin. Number of melanocytes will be counted in basal later using immunohistochemistry. Any inflammatory reaction around the dermal melanocytes or in dermis will also be studied. Any epidermal changes will also be studied.